Crossmark

Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment

Crossref DOI link: https://doi.org/10.1007/s11030-024-10812-0

Published Online: 2024-03-06

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shivakumar,

Dinesha, P.

Udayakumar, D.
License Information

Text and Data Mining valid from 2024-03-06

Version of Record valid from 2024-03-06
More Information

Article History

Received: 28 November 2023

Accepted: 13 January 2024

First Online: 6 March 2024

Declarations

:

: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Document is current

Any future updates will be listed below